<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A phase I study of irinotecan <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (<z:chebi fb="9" ids="27656">CPT</z:chebi>-11), <z:chebi fb="2" ids="31355">carboplatin</z:chebi>, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> treatment in 7 patients with relapsed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 7 patients with refractory <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was conducted to evaluate the maximal tolerated dose </plain></SENT>
<SENT sid="1" pm="."><plain>The 6 female and 8 male patients had a median age of 63 years (range, 45-73 years), a median performance status of 0 (range, 0-2), and a median disease stage of IV </plain></SENT>
<SENT sid="2" pm="."><plain>This study included patients with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 5), adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 2), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 2), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 2), angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1), anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1), and Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had received <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-containing combination chemotherapy prior to this therapy </plain></SENT>
<SENT sid="4" pm="."><plain>The starting dosage of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 was 15 mg/m2 per day (days 1-3 and 8-10), and dosage-escalation increments of 5 mg/m2 per day were planned, with fixed dosages of <z:chebi fb="2" ids="31355">carboplatin</z:chebi> (250 mg/m2 per day, day 1) and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> (40 mg/body, days 1-3 and days 8-10) </plain></SENT>
<SENT sid="5" pm="."><plain>Five patients were enrolled at level 1, 3 at level 2, 4 at level 3, and 2 at level 4 </plain></SENT>
<SENT sid="6" pm="."><plain>Ten patients (71%) and 11 patients (79%) experienced grade 3 or 4 hematologic toxicities of <z:mp ids='MP_0000221'>leukocytopenia</z:mp> and <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients (29%) and 9 patients (64%) experienced grade 3 or 4 <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and <z:hpo ids='HP_0001903'>anemia</z:hpo>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients who received 30 mg/m2 (level 4) of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 developed <z:hpo ids='HP_0100806'>sepsis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>We concluded that the recommended dose of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 with <z:chebi fb="2" ids="31355">carboplatin</z:chebi> and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> is 25 mg/m2 </plain></SENT>
<SENT sid="10" pm="."><plain>No <z:hpo ids='HP_0011420'>deaths</z:hpo> were related to this chemotherapy, and no patient developed <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The overall response rate was 36% </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude that the combination therapy of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11, <z:chebi fb="2" ids="31355">carboplatin</z:chebi>, and dexamthasone is effective as salvage therapy but that the duration of response is too short </plain></SENT>
</text></document>